Published in Gene Therapy Weekly, January 16th, 2003
The methods, developed by David T. Curiel, MD, founder of VectorLogics and professor and head of the Gene Therapy Center at the University of Alabama, involve the modification of structures located on the surface of the oncolytic virus that play a key role in directing the viruses to target, penetrate, and ultimately destroy cancer cells. Financial terms of the collaboration were not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.